Clearly, in my reckoning, the results to date (which are...

Clearly, in my reckoning, the results to date (which are critical before further progress is made) are
very encouraging. Without meaningful and material success to date, I just cannot see why the Co
would be embarking on further professional personal expansion - Very unlikely that all the latest
(and prospective) appointments would be made if the Co was expecting an unsuccessful scenario.

It would be critical from an economic sense to be sure that positive progress is made first in the
current tech and trial before expanding the professional payroll further - That's why I believe that
these little clues provide validation and proof of ultimate success here.

These little clues, the expansion of premises in the US, and numerous professional appointments
throughout 2022 may not move the needle enough, but, confirmation of successful trial completion
(which I fully expect before year-end) most definitely would.